Role of RANK ligand in mediating increased bone resorption in early postmenopausal women
Open accessThe DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
Studies in rodents have implicated various cytokines as paracrine mediators of increased osteoclastogenesis during estrogen deficiency, but increases in RANKL, the final effector of osteoclastogenesis, have not been demonstrated. Thus, we isolated bone marrow mononuclear cells expressing RANKL on their surfaces by two-color flow cytometry using FITC-conjugated osteoprotegerin-Fc (OPG-Fc-FITC) as a probe. The cells were characterized as preosteoblastic marrow stromal cells (MSCs), T lymphocytes, or B lymphocytes by using Ab's against bone alkaline phosphatase (BAP), CD3, and CD20, respectively, in 12 premenopausal women (Group A), 12 early postmenopausal women (Group B), and 12 age-matched, estrogen-treated postmenopausal women (Group C). Fluorescence intensity of OPG-Fc-FITC, an index of the surface concentration of RANKL per cell, was increased in Group B over Groups A and C by two- to threefold for MSCs, T cells, B cells, and total RANKL-expressing cells. Moreover, in the merged groups, RANKL expression per cell correlated directly with the bone resorption markers, serum C-terminal telopeptide of type I collagen and urine N-telopeptide of type I collagen, in all three cell types and inversely with serum 17beta-estradiol for total RANKL-expressing cells. The data suggest that upregulation of RANKL on bone marrow cells is an important determinant of increased bone resorption induced by estrogen deficiency.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In humans, estrogen deficiency is associated with an expansion of RANKL-and TNF-expressing T cells and B cells (27,28,30,31).”
From Sex steroid deficiency-associated bone loss is microbiota dependent and prevented by probiotics (2016) · cites this paper as [27]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“RANKL levels were increased on the surface of bone marrow cells from early postmenopausal women who are estrogen deficient”
From Pathogenesis of osteoporosis: concepts, conflicts, and prospects (2005) · cites this paper as [48]
In the citing paper
“Moreover, estrogen stimulates these bone cells to produce osteoprotegerin (OPG), a decoy receptor of RANK in osteoclast, thus inhibiting osteoclastogenesis [19, 155–159].”
From Biology of Bone Tissue: Structure, Function, and Factors That Influence Bone Cells (2015) · cites this paper as [157]
In the citing paper
“In humans, estrogen deficiency is associated with increased RANKL expression by bone marrow osteoblastic, T and B cells, whereas estrogen treatment reversed this increase ( 76).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [76]
In the citing paper
“flow cytometry studies conducted with bone marrow aspirates from postmenopausal subjects showed that saturating levels of OPG did not reduce the ability of anti-TRAIL antibodies to recognize TRAIL-positive cells (76).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [76]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.
Lacey, D. L., Timms, E., Tan, H.-L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81569-x · Cited by 5,439
Self-citationOsteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130
Self-citationYasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S.-I., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.7.3597 · Cited by 4,228
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph node organogenesis.
Kong, Y.-Y., Yoshida, H., Sarosi, I., Tan, H.-L., Timms, E., Capparelli, C., Morony, S., Oliveira-dos-Santos, A. J., Van, G., Itie, A., et al. (1999) · Nature · doi:10.1038/16852 · Cited by 3,351 · cited 1×
“The expression of RANKL by T cells may be related, in part, to their function as immunoregulators, because targeted disruption of the RANKL gene results in mice lacking lymph nodes and with defective T and B lymphocyte differentiation (45).”
BackgroundSelf-citationManolagas, S. C. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.2.0395 · Cited by 2,568
Estrogen Resistance Caused by a Mutation in the Estrogen-Receptor Gene in a Man
Smith, E. P., Boyd, J., Frank, G. R., Takahashi, H., Cohen, R. M., Specker, B., Williams, T. C., Lubahn, D. B., & Korach, K. S. (1994) · New England Journal of Medicine · doi:10.1056/nejm199410203311604 · Cited by 2,471 · cited 1×
“For example, ERα knockout mice have short limbs and mild osteopenia (31), whereas a young adult male with homozygous null mutations of ERα had elongated limbs and a greater degree of osteopenia (32).”
BackgroundSuda, T., Takahashi, N., Udagawa, N., Jimi, E., Gillespie, M. T., & Martin, T. J. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.3.0367 · Cited by 2,336
Estrogen Receptor Null Mice: What Have We Learned and Where Will They Lead Us?
Couse, J. F., & Korach, K. S. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.3.0370 · Cited by 2,045
Kong, Y.-Y., Feige, U., Sarosi, I., Bolon, B., Tafuri, A., Morony, S., Capparelli, C., Li, J., Elliott, R., McCabe, S., et al. (1999) · Nature · doi:10.1038/46303 · Cited by 1,856 · cited 1×
“In an experimental mouse model of inflammatory arthritis, activated T lymphocytes expressing RANKL were shown to regulate the associated periarticular bone loss and joint destruction (46).”
BackgroundSelf-citationSex Steroids and the Construction and Conservation of the Adult Skeleton
Riggs, B. L., Khosla, S., & Melton, L. J. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.3.0465 · Cited by 1,846
Self-citation
Research works printed but not linked: 8
- 10.1210/jc.87.4.1443 · doi:10.1210/jc.87.4.1443 · Paper page
- 10.1210/en.142.12.5050 · doi:10.1210/en.142.12.5050 · Paper page
- 10.1210/en.140.9.4367 · doi:10.1210/en.140.9.4367 · Paper page
- 10.1210/en.142.6.2205 · doi:10.1210/en.142.6.2205 · Paper page
- 10.1210/jc.87.4.1550 · doi:10.1210/jc.87.4.1550 · Paper page
- 10.1210/en.141.12.4768 · doi:10.1210/en.141.12.4768 · Paper page
- Owen, 1988, Ciba Found. Symp., 136, 42
- 10.1002/1521-4141(200208)32:8<2246::AID-IMMU2246>3.0.CO;2-6 · DOI
Cited by
Items 501–600 of 821
New insights into the gene function of osteoporosis
You, L., Chen, L., Pan, L., & Chen, J.-Y. (2013) · Frontiers in bioscience · doi:10.2741/4165 · Cited by 14
Denosumab for treatment of postmenopausal osteoporosis
Chitre, M. M., Shechter, D., & Grauer, A. (2011) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp100493 · Cited by 12
Sanyal, A., Riggs, B. L., Spelsberg, T. C., & Khosla, S. (2004) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20291 · Cited by 12
“In addition, these cells are critical for the support of osteoclastogenesis through their production of RANKL,which has recently been shown to be regulated by estrogen in vivo [Eghbali-Fatourechi et al., 2003].”
BackgroundInfluentialSelf-citationEffect of dietary legumes on bone-specific gene expression in ovariectomized rats
Park, Y., Moon, H.-J., Paik, D., & Kim, D. (2013) · Nutrition Research and Practice · doi:10.4162/nrp.2013.7.3.185 · Cited by 14
“Estrogen deficiency leads to an up-regulation of receptor activator of nuclear factor κB ligand (RANKL) on bone marrow cells, which is an important determinant of increased bone resorption [4], whereas estrogen itself stimulates osteoprotegerin (OPG) production in osteoblasts and thus exerts anti-resorptive effects on…”
BackgroundQiu, X., Wang, L., Gui, Y., Xu, Y., & Li, D. (2015) · PubMed Central · Cited by 12
Sato, M., Inage, K., Sakuma, Y., Sato, J., Orita, S., Yamauchi, K., Eguchi, Y., Ochiai, N., Kuniyoshi, K., Aoki, Y., et al. (2015) · European Spine Journal · doi:10.1007/s00586-015-4058-z · Cited by 12
“increased production of the proinflammatory cytokines TNF-a, NF-kB, and RANKL [8, 28, 29].”
BackgroundOsteoprotegerin as a potential therapy for osteoporosis
Hamdy, N. A. T. (2005) · Current Osteoporosis Reports · doi:10.1007/s11914-996-0014-5 · Cited by 16
Takami, K., Okamoto, K., Etani, Y., Hirao, M., Miyama, A., Okamura, G., Goshima, A., Miura, T., Kurihara, T., Fukuda, Y., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.171962 · Cited by 12
Pivonka, P., Calvo‐Gallego, J. L., Schmidt, S., & Martínez‐Reina, J. (2024) · Bone · doi:10.1016/j.bone.2024.117140 · Cited by 12
Effect of esculetin on bone metabolism in ovariectomized rats
Meijie, L., Ruihai, W., Li, Y., Dong, B., Jinghua, P., Liu, H., Shaojun, W., Jiaying, W., Gang, S., Qing, M., et al. (2018) · 中医杂志:英文版 · doi:10.1016/s0254-6272(18)30989-0 · Cited by 11
Role of Mast-Cell-Derived RANKL in Ovariectomy-Induced Bone Loss in Mice
Fischer, V., Bülow, J. M., Krüger, B. T., Ragipoglu, D., Vikman, A., Haffner‐Luntzer, M., Katsoulis‐Dimitriou, K., Dudeck, A., & Ignatius, A. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119135 · Cited by 14
On the Evolution and Contemporary Roles of Bone Remodeling
Kostenuik, P. J. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-415853-5.00037-6 · Cited by 16
Kim, S., Kim, H. J., Park, G. E., Pandey, R. P., Lee, J., Sohng, J. K., & Park, Y. I. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119074 · Cited by 11
The osteoporosis revolution marches on
Raisz, L. G. (2007) · Journal of Orthopaedic Science · doi:10.1007/s00776-007-1133-2 · Cited by 14
“Thus, estrogen administration can decrease bone resorption by decreasing the ability of marrow cells to respond to stimulation by receptor activator of NFκB (RANKL) and by decreasing the expression of RANKL in marrow cells.(25,26) We are still not sure whether the RANKL-expressing cells that are affected by estrogen a…”
BackgroundTreatment of immobilization-related hypercalcaemia with denosumab
Malberti, F. (2012) · Clinical Kidney Journal · doi:10.1093/ckj/sfs133 · Cited by 13
“An excess of RANKL is found in many clinical conditions such as oestrogen deficiency [21], systemic glucocorticoid exposure [22], active inflammatory process in rheumatoid arthritis [23], skeletal malignancies such as multiple myeloma [24] and bone metastases [25], resulting in exacerbated bone loss.”
BackgroundDenosumab for the Management of Postmenopausal Osteoporosis
Singer, A. J., & Grauer, A. (2010) · Postgraduate Medicine · doi:10.3810/pgm.2010.11.2235 · Cited by 11
Iwai, K., Ishii, M., Ohshima, S., Miyatake, K., & Saeki, Y. (2007) · Rheumatology International · doi:10.1007/s00296-007-0424-4 · Cited by 15
“osteoclastogenesis, either by aVecting stromal/osteopblastic cell function for producing RANKL or osteoprotegerin (OPG), a decoy receptor that can block RANK/RANKL interaction [18, 22], or by modulating T cell cytokine production [23, 24].”
BackgroundLow Bone Mineral Density, HIV Infection, and Women: Fracture or Fiction?
Yin, M. T., & Glesby, M. J. (2006) · Clinical Infectious Diseases · doi:10.1086/501025 · Cited by 11
Bone Loss and Fractures in Post-Menopausal Women Living with HIV: A Narrative Review
Jamshaid, M., Heidari, A., Hassan, A. M., Mital, D., Pearce, O., Panourgia, M. P., & Ahmed, M. H. (2024) · Pathogens · doi:10.3390/pathogens13090811 · Cited by 15
“In the context of women and menopause, both B-cells and T-cells have been shown to be key sources of enhanced RANKL production in post-menopausal women relative to premenopausal women and post-menopausal women receiving oestrogen replacement [68].”
Nucleic acid aptamers in orthopedic diseases: promising therapeutic agents for bone disorders
He, Z., Peng, Q., Bin, W., Zhao, L., Chen, Y., Zhang, Y., Yang, W., Yan, X., & Liu, H. (2025) · Bone Research · doi:10.1038/s41413-025-00447-8 · Cited by 13
“109 It stimulates osteoclastogenesis while suppressing osteoclast apoptosis.”
An, Z., Wu, B., Mao, W., & Wu, L. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1638629 · Cited by 13
“Research indicates that postmenopausal women in early stages exhibit higher RANKL expression in bone marrow mononuclear cells (MNCs) compared to premenopausal women (18).”
Mochizuki, T., Yano, K., Ikari, K., Hiroshima, R., Nasu, Y., & Okazaki, K. (2020) · Modern Rheumatology · doi:10.1080/14397595.2020.1812793 · Cited by 10
“RANKL has been identified as an essential cytokine for the differentiation, function, formation, activation, and survival of osteoclasts [5,10–12].”
BackgroundInfluentialInteractions Among Osteoblasts, Osteoclasts, and Other Cells in Bone
Martin, T. J., Sims, N. A., & Quinn, J. M. W. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-375670-1.10008-1 · Cited by 16
Effect of Nicotine on RANKL and OPG and Bone Mineral Density
Mızrak, S., Turan, V., İnan, S., Uysal, A., Yılmaz, C., & Ercan, G. (2014) · Journal of Investigative Surgery · doi:10.3109/08941939.2014.916369 · Cited by 11
“While in some studies, no link was found between serum RANKL and BMD scores [24, 26], in others, an inverse correlation was shown [6, 23].”
ResultWu, G., Chen, J., Lin, P.-I., Cherng, Y., Yang, S., & Chen, R. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118195 · Cited by 12
Effects of letrozole on bone biomarkers and femur fracture in female rats
Yönden, Z., Aydin, M., Alçin, E., Keleştemur, M. H., Kutlu, S., & Yılmaz, B. (2009) · Journal of Physiology and Biochemistry · doi:10.1007/bf03180579 · Cited by 10
“Estrogen depletion may increase receptor activator of nuclear factor-kappa beta ligand (RANKL) (22) which binds to the receptor on osteoclasts.”
BackgroundSipos, W., Duvigneau, J. C., Schmoll, F., Exel, B., Hofbauer, G., Baravalle, G., Hartl, R. T., Dobretsberger, M., & Pietschmann, P. (2005) · Zentralblatt für Veterinärmedizin Reihe A · doi:10.1111/j.1439-0442.2005.00755.x · Cited by 16
Gallina, S., Piedra, S. B., Torrés-Lagares, D., Baroukh, B., Llorens, A., Pérez, J. L. G., Jl, S., Cherruau, M., & Lesclous, P. (2009) · Journal of Periodontology · doi:10.1902/jop.2009.090297 · Cited by 10
Burn Injury Has Skeletal Site-Specific Effects on Bone Integrity and Markers of Bone Remodeling
Hoscheit, M. J., Conner, G. R., Roemer, J., Vuchkovska, A., Abbasnia, P., Vana, P. G., Shankar, R., Kennedy, R. H., & Callaci, J. J. (2016) · Journal of Burn Care & Research · doi:10.1097/bcr.0000000000000389 · Cited by 10
Zojer, N., Brenner, K., Beke, D., Kudlacek, S., Hawa, G., Woloszczuk, W., Hofbauer, L. C., & Pecherstorfer, M. (2005) · PubMed · Cited by 12
Aberrant Activation of the RANK Signaling Receptor Induces Murine Salivary Gland Tumors
Szwarc, M. M., Kommagani, R., Jacob, A. P., Dougall, W. C., Ittmann, M., & Lydon, J. P. (2015) · PLoS ONE · doi:10.1371/journal.pone.0128467 · Cited by 9
“In keeping with its pleiotropic role in normal physiology, deregulation of the RANKL/ RANK signaling axis underlies the initiation and/or progression of numerous pathophysiologies, including rheumatoid arthritis (an autoimmune disorder) [6], postmenopausal osteoporosis [7], and rare familial bone pathologies (i.”
BackgroundBalsa, J. A., Lafuente, C., Gómez‐Martín, J. M., Galindo, J., Peromingo, R., García‐Moreno, F., Velasco, G. R., Martínez-Botas, J., Gómez‐Coronado, D., Escobar-Morreale, H. F., et al. (2015) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-015-0712-0 · Cited by 11
“Nevertheless, the involvement of the OPG/RANKL system may be even more important in patients with osteoporosis, as already shown for idiopathic or postmenopausal osteoporosis [30–32].”
BackgroundMa, T.-L., Zhu, P., Ke, Z.-R., Chen, J.-X., Hu, Y.-H., & Xie, J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.891313 · Cited by 9
Mori, K., Suzuki, K., Hozumi, A., Goto, H., Tomita, M., Koseki, H., Yamashita, S., & Osaki, M. (2014) · Biomedical Research · doi:10.2220/biomedres.35.153 · Cited by 11
“Marrow stromal cells obtained from postmenopausal osteoporotic patients displayed pronounced tendency to adipogenic differentiation (6, 7).”
BackgroundMahendra, J., Svedha, P., Theayarajar, R., & Namachivayam, A. (2017) · Journal of Indian Society of Periodontology · doi:10.4103/jisp.jisp_43_16 · Cited by 9
“[25] There was a decrease in BMD of dual femur and spine in postmenopausal periodontitis women (Group C) as compared to Groups A and B which was found to be statistically signi fi cant [Table 1].”
Pathophysiology of Osteoporosis
Raisz, L. G., Bilezikian, J. P., & Martin, T. J. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-373884-4.00082-3 · Cited by 13
Kim, S., Kim, H. J., Park, G. E., Lee, C. W., Synytsya, A., Capek, P., & Park, Y. I. (2022) · Marine Biotechnology · doi:10.1007/s10126-022-10136-w · Cited by 9
“Therefore, antagonizing RANKL binding to RANK on the surface of osteoclastic cells and/or suppressing subsequent RANKL-RANK intracellular downstream signaling events inhibit excessive osteoclastic cell differentiation and function, representing a therapeutic target for pathological bone loss diseases such as OP (Eghba…”
BackgroundTurbo methanol extract inhibits bone resorption through regulation of T cell function
Balakrishnan, B., Indap, M. M., Singh, S. P., Krishna, C. M., & Chiplunkar, S. V. (2013) · Bone · doi:10.1016/j.bone.2013.10.008 · Cited by 10
“resorption [6,40].”
Rugo, H. S. (2007) · Clinical Breast Cancer · doi:10.3816/cbc.2007.s.003 · Cited by 10
The Potential of Probiotics as a Therapy for Osteoporosis
Collins, F. L., Rios‐Arce, N. D., Schepper, J. D., Parameswaran, N., & McCabe, L. R. (2018) · ASM Press eBooks · doi:10.1128/9781555819705.ch9 · Cited by 15
Brunetti, G., Benedetto, A. D., & Mori, G. (2013) · Springer eBooks · doi:10.1007/978-88-470-5483-7_3 · Cited by 12
Liu, P. Y., Hoey, K. A., Mielke, K. L., Veldhuis, J. D., & Khosla, S. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1583 · Cited by 9
Self-citationMechanisms of Estrogen Action in Bone
Pacifici, R. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-373884-4.00059-8 · Cited by 10
Estrogen, Bone Homeostasis, and Osteoporosis
Riggs, B. L., Khosla, S., & Melton, L. J. (2008) · Elsevier eBooks · doi:10.1016/b978-012370544-0.50042-2 · Cited by 13
Self-citationWang, S., Greenbaum, J., Qiu, C., Gong, Y., Wang, Z., Lin, X., Liu, Y., He, P., Meng, X., Zhang, Q., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1107511 · Cited by 10
“In addition, postmenopausal osteoporosis has been described as an inflammatory disease, as immune cells were identified as key players in the onset of osteoporosis (6, 7).”
BackgroundEvidence in humans for bone as an endocrine organ regulating energy metabolism
Khosla, S. (2023) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2023.100471 · Cited by 15
Self-citationThe p53-miR17 family-Rankl axis bridges liver-bone communication
Ma, G., Cheng, S., Han, Y., Tang, W., Pang, W., Chen, L., Ding, Z., & Cao, H. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.12.046 · Cited by 10
RANK/RANKL Signaling Pathway in Breast Development and Cancer
Pérez-Chacón, G., Santamaría, P. G., Redondo-Pedraza, J., & González‐Suárez, E. (2025) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-70875-6_16 · Cited by 10
A review of the relationship between gut microbiota and osteoporosis in high altitude environments
Qiao, Y., Zheng, H., Cheng, R., Rong, L., Guo, J., Li, G., Wei, L., Gao, T., Shan, Z., & Bi, H. (2025) · Journal of Health Population and Nutrition · doi:10.1186/s41043-025-00994-0 · Cited by 11
“Studies have shown that estrogen enhances OPG production in osteoblasts by inhibiting RANKL expression in CD 3 T cells and CD 20 B cells [43].”
Zeng, Q., Xu, R., Ling, H., Zhao, S., Wang, X., Yuan, W., Gu, M., Xu, T., Wang, P., Ruan, H., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.925848 · Cited by 10
“During the postmenopausal period, the expression of various inflammation inhibitors was found to decrease, but RANKL increased significantly, suggesting a critical role for RANKL in PMOP (23).”
BackgroundVertebral marrow fat fraction is associated with circulating RANKL in postmenopausal females
Li, X., Zuo, X., Li, L., Xu, R., Wang, Y., Chang, S., Wang, Y., Luo, P. F., & Li, G. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1442046 · Cited by 8
Huang, J., Thulin, M. H., Damber, J., & Welén, K. (2021) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2021.111380 · Cited by 10
“Estrogen inhibits bone resorption by osteoclasts by shifting the balance of osteoprotegerin (OPG)/receptor activator of RANKL secretion from osteoblasts as well as limiting the number of tumor necrosis factor-producing T-cells [19-23].”
BackgroundTreatment of fibrous dysplasia: focus on denosumab
Huzum, B., Antoniu, S. A., & Dragomir, R. A. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2022118 · Cited by 9
Osteoporosis – fracture healing and osseointegration
Alghamdi, H. S., van den Beucken, J. J. J. P., & Jansen, J. A. (2014) · Drug Discovery Today Disease Models · doi:10.1016/j.ddmod.2014.10.001 · Cited by 8
“Consequently, in postmenopausal women, it has been shown that the RANKL level as well as osteoclastic activity is increased in response to the low estrogen-hormone level [18].”
BackgroundEffects of brucine on bone metabolism in multiple myeloma
Ma, Y., Zhao, J., Wang, Y., Li, Z., Feng, J. Q., & Ren, H. (2012) · Molecular Medicine Reports · doi:10.3892/mmr.2012.920 · Cited by 9
The Potential of Indole Alkaloids in Bone Health and Osteoporosis Management
Caruso, A., Caira, V., El‐Kashef, H., & Saturnino, C. (2024) · Applied Sciences · doi:10.3390/app14188124 · Cited by 7
Osteoprotegerin: regulator, protector and marker
Othmane, T., Speer, G., Fekete, B., Szabó, T., Egresits, J., Fodor, E., Kiss, I., Nemcsik, J., Szabó, A., Németh, Z., et al. (2008) · Orvosi Hetilap · doi:10.1556/oh.2008.28470 · Cited by 7
Study on the mechanism of NLRP3 effect on the skeleton of de-ovalized mice
Yang, C., Song, B., Han, L., & Gao, Z. (2023) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2023.101496 · Cited by 12
Li, S., Zou, J., Ran, J., Wang, L., Nie, G., Liu, Y., Tian, C., Yang, X., Liu, Y., Wan, J., et al. (2024) · International Journal of General Medicine · doi:10.2147/ijgm.s494759 · Cited by 9
“27 The interaction between RANKL and its receptor RANK triggers a cascade of signaling events leading to osteoclast differentiation and maturation.”
Development of an inflammatory tissue-selective chimeric TNF receptor
Lee, C., Wang, C.-C., Chen, M. J., Chuang, K., Cheng, T., Jian, T.-Y., Wang, Y., Huang, T., Liao, K., & Tzou, S. (2018) · Cytokine · doi:10.1016/j.cyto.2018.10.003 · Cited by 7
Cellular Contributors to Bone Homeostasis
Rauner, M., Jähn, K., Hemmatian, H., Colditz, J., & Goettsch, C. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-46725-8_16 · Cited by 7
Chandra, A., Rosenzweig, A. B., & Pignolo, R. J. (2018) · Springer eBooks · doi:10.1007/978-3-319-72228-3_1 · Cited by 7
Immune System and Postmenopausal Bone Loss
D’Amelio, P., & Isaia, G. C. (2009) · Clinical Reviews in Bone and Mineral Metabolism · doi:10.1007/s12018-009-9061-7 · Cited by 8
“It has recently been reported that RANKL expression on lymphocytes and marrow stromal cells is significantly elevated during estrogen deficiency in humans and correlates directly with increases in bone resorption markers and inversely with serum estrogen levels [14] and that in postmenopausal women, production of cyto…”
BackgroundDo γδ T cells predict osteonecrosis of the jaw?
Weitzmann, M. N. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1886 · Cited by 9
“Indeed, RANKL and/or TNFa, derived in part from activated T cells, have been implicated in bone loss and joint destruction in animal models of rheumatoid arthritis,((13)) alveolar bone loss in periodontal infection,((14,15)) and in humans and animal models of the archetypal osteoporotic bone disease, postmenopausal os…”
BackgroundSex Steroid Effects on Bone Metabolism
Monroe, D. G., Spelsberg, T. C., & Khosla, S. (2006) · Elsevier eBooks · doi:10.1016/b978-012088562-6/50020-0 · Cited by 8
Self-citation-643C > T RANKL gene polymorphism is associated with osteoporosis in Tunisian postmenopausal women
Sassi, R., Sahli, H., Cheour, E., Sellami, S., & Gaaied, A. B. A. E. (2017) · Climacteric · doi:10.1080/13697137.2017.1315088 · Cited by 10
SPA0355 prevents ovariectomy-induced bone loss in mice
Ha, S. H., Zhang, Z., Moon, Y. J., Park, I. W., Cho, Y. G., Jeon, R., & Park, B. (2019) · Korean Journal of Physiology and Pharmacology · doi:10.4196/kjpp.2019.23.1.47 · Cited by 7
“Especially, upon activation of RANK through binding of RANKL, the MAPKs, Akt, and NF- B pathways are activated in osteoclasts [3-5].”
BackgroundNanes, M. S., & Pacifici, R. (2005) · Springer eBooks · doi:10.1007/1-84628-016-8_5 · Cited by 8
The Role of Estrogen Receptor in Bone Cells
Millán, M. M. (2015) · Clinical Reviews in Bone and Mineral Metabolism · doi:10.1007/s12018-015-9188-7 · Cited by 10
Pathophysiologie und Pathomorphologie der Osteoporose
Priemel, M., Münch, C., Beil, F. T., Ritzel, H., & Amling, M. (2006) · Der Radiologe · doi:10.1007/s00117-006-1413-4 · Cited by 18
Aging and menopause reprogram osteoclast precursors for aggressive bone resorption
Møller, A. M. J., Delaissé, J.-M., Olesen, J. B., Madsen, J. S., Canto, L. M., Bechmann, T., Rogatto, S. R., & Søe, K. (2020) · Bone Research · doi:10.1038/s41413-020-0102-7 · Cited by 6
Hamedi, F., Alizadeh, M., & Kheirouri, S. (2025) · Bone · doi:10.1016/j.bone.2025.117622 · Cited by 7
Ma, L., Wang, Y., Qiu, S., Shi, M., Tang, W., Hu, H., Li, C., Lu, H., & Wang, X. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02910-1 · Cited by 7
“RANKL binds to its receptor RANK on osteoclast precursors and metastatic cells, activating NF-κ B signalin, promoting osteoclast differentiation and enhancing bone-resorbing activity [71].”
Cheng, B., Wang, T., Kang, H., Lin, Y., Huang, C.-C., Hsu, T., Kung, F., & Huang, K. (2013) · Taiwanese Journal of Obstetrics and Gynecology · doi:10.1016/j.tjog.2013.04.008 · Cited by 8
“RANKL binds to its receptor RANK on osteoclast precursor cells and activates osteoclastogenesis leading to an increase in the number of osteoclasts and a decrease in BMD [6].”
Backgroundvan Leeuwen, J. P. T. M., van der Eerden, B. C. J., van de Peppel, J., Stein, G. S., & Lian, J. B. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-415853-5.00009-1 · Cited by 12
Lu, Y.-H., Geng, J., Wu, D., Chen, S., Hung, C., & Kuo, C. (2021) · Nutrients · doi:10.3390/nu13103655 · Cited by 6
Osteoclasts directly influence castration-resistant prostate cancer cells
Huang, J., Freyhult, E., Buckland, R. J., Josefsson, A., Damber, J., & Welén, K. (2022) · Clinical & Experimental Metastasis · doi:10.1007/s10585-022-10179-2 · Cited by 7
Exploiting new targets for old bones
Rosen, C. J. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.91 · Cited by 6
Role of interleukin-6 on RANKL-RANK/osteoprotegerin system in hypothyroid ovariectomized mice.
Myśliwiec, J., Zbucki, R. L., Nikołajuk, A., Myśliwiec, P., Taranta, A., Kamiński, K. A., Bondyra, Z., Dadan, J., Górska, M., & Winnicka, M. M. (2011) · Folia Histochemica et Cytobiologica · doi:10.2478/v10042-010-0064-5 · Cited by 6
Lee, H., Wu, C., Lin, Y., Hwang, J.-S., Wu, C.-H., & Chu, P. (2017) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2017.04.021 · Cited by 6
Yoshida, T., Wang, J., & Stern, P. H. (2019) · Handbook of experimental pharmacology · doi:10.1007/164_2019_327 · Cited by 6
Osteopenia/Osteoporosis and Its Association with Sarcopenia: EpiFloripa Aging Study 2013/2014
Confortin, S. C., Ono, L. M., Marques, L. P., Ceolin, G., d’Orsi, E., & Barbosa, A. R. (2020) · Portuguese Journal of Public Health · doi:10.1159/000508924 · Cited by 8
Eleni, D., & Tsalikis, L. (2014) · Journal of Dental Implants · doi:10.4103/0974-6781.130946 · Cited by 6
Martín-Fernández, M., Garzón-Márquez, F., Díaz Curiel, M., Prieto‐Potín, I., Álvarez, L., Guede, D., Caeiro-Rey, J. R., & de la Piedra, C. (2018) · The Aging Male · doi:10.1080/13685538.2018.1499082 · Cited by 6
Wong, S. C., Straub, V. W., Ward, L. M., Quinlivan, R. C. M., Adachi, J., Ahmed, S. F., Anderton, M., Broggi, F., Crabtree, N. J., de Groot, I. J. M., et al. (2019) · Neuromuscular Disorders · doi:10.1016/j.nmd.2019.01.002 · Cited by 6
Pathophysiology of postmenopausal osteoporosis
Ferrari, S., & Ringe, J. D. (2010) · doi:10.1007/978-1-907673-28-3_1 · Cited by 9
Chapter 41. Role of Sex Steroids in the Pathogenesis of Osteoporosis
Drake, M. T., & Khosla, S. (2008) · Wiley eBooks · doi:10.1002/9780470623992.ch41 · Cited by 7
Self-citation(2010) · Human Kinetics eBooks · doi:10.5040/9781492595700.ch-0011 · Cited by 6
Sex Steroids and the Pathogenesis of Osteoporosis
Drake, M. T., & Khosla, S. (2018) · Wiley eBooks · doi:10.1002/9781119266594.ch52 · Cited by 8
Self-citationHaroon, S., Cobb, C., Sufian, S., Jain, R., Maalouf, N. M., & Putman, M. S. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.04.011 · Cited by 6
Terhaar, H., Duck, B., Collins, C., Grant, E., Pride, L. S., Zhang, D., Zineldin, E., Burrows, P. D., Javed, A., & Khass, M. (2025) · Current Osteoporosis Reports · doi:10.1007/s11914-025-00947-w · Cited by 6
“Interestingly, increased OPG expression by B cells favors bone synthesis over resorption during remodeling [66, 67 ].”
Kahla, R. B., & Barkaoui, A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-88467-9.00002-3 · Cited by 6
Shirinsky, V. S., & Shirinsky, I. V. (2022) · Medical Immunology (Russia) · doi:10.15789/1563-0625-oai-1521 · Cited by 6
Rethinking Osteoporosis Drugs: Can We Simultaneously Address Sarcopenia?
Gavrilov, Z., & Lojk, J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146924 · Cited by 7
“RANKL expression increases in postmenopausal women due to the reduction in estrogen levels and is the driving force behind postmenopausal osteoporosis [79].”
Takizawa, A., Chiba, M., Ōta, T., Yasuda, M., Suzuki, K., Kanemitsu, T., Itoh, T., Shinoda, H., & Igarashi, K. (2016) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2016.04.011 · Cited by 5
Bouzid, A., Chelly, A., Tekari, A., Singh, N., Hansdah, K., Achour, I., Ayed, I. B., Jbeli, F., Charfeddine, I., Ramchander, P. V., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.870244 · Cited by 5
Ledoux, C., Boaretti, D., Sachan, A., Müller, R., & Collins, C. J. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.901720 · Cited by 9
“Note that, as has been extensively reviewed elsewhere, for modeling purposes a question even more critical than the estrogen concentrations themselves may be the parameters relating to the effect of estrogen on bone cells as various occasionally conflicting mechanisms have been reported (Finkelman et al., 1992; Tomkin…”
Sex-Specific Effects of THRβ Signaling on Metabolic Responses to High Fat Diet in Mice
Muralidharan, A., Gomez, G. A., Kesavan, C., Pourteymoor, S., Larkin, D., Tambunan, W., Sechriest, V. F., & Mohan, S. (2024) · Endocrinology · doi:10.1210/endocr/bqae075 · Cited by 5
Ostéoporose et traitement hormonal substitutif
Roux, C. (2005) · La Presse Médicale · doi:10.1016/s0755-4982(05)83927-2 · Cited by 6
The role of rank-ligand inhibition in the treatment of postmenopausal osteoporosis
VARENNA, M., & Gatti, D. (2011) · Reumatismo · doi:10.4081/reumatismo.2010.163 · Cited by 7
“Studi recenti hanno definitivamente dimostrato che la carenza estrogenica nella donna è in grado di indurre un’iperespressione di RANKL nell’ambiente midollare, diversamente da quanto si osserva in premenopausa o quando la menopausa viene trattata con una terapia estrogenica sostitutiva (18).”
Background
Metadata
- Authors
- Eghbali-Fatourechi, G., Khosla, S., Sanyal, A., Boyle, W. J., Lacey, D. L., & Riggs, B. L.
- Affiliations
- Mayo Clinic (US)
- Amgen (United States) (US)
- Corresponding author
- Riggs, B. Lawrence
- Venue
- Journal of Clinical Investigation
- Published
- 2003-04-15
- Volume
- 111
- Issue
- 8
- Pages
- 1221-1230
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC152939
- OpenAlex
- W4254761345
- Cited by
- 825
- References
- 44
- Citations by year
- 2026: 16 · 2025: 24 · 2024: 28 · 2023: 25 · 2022: 34 · 2021: 36 · 2020: 41 · 2019: 30 · 2018: 39 · 2017: 39 · 2016: 33 · 2015: 45 · 2014: 31 · 2013: 42 · 2012: 52
- FWCI
- 11.38
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Amgen
- National Institutes of Health (M01-RR00 585, AG 04875, RR-00585)
- U.S. Public Health Service (AG-04875)
- National Institute on Aging (P01-AG04875, P01AG004875)
- National Center for Research Resources (M01-RR00 585, M01RR000585)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Keywords
- RANK ligand, bone resorption, postmenopausal osteoporosis, estrogen deficiency, osteoclastogenesis, mesenchymal stem cells, T cells, B cells, osteoprotegerin, estradiol, bone turnover markers, paracrine signaling
- MeSH terms
- Adult, Bone Resorption, Carrier Proteins, Female, Flow Cytometry, Glycoproteins, Humans, Membrane Glycoproteins, Middle Aged, Tumor Necrosis Factor-alpha, Osteoporosis, Postmenopausal, Receptors, Tumor Necrosis Factor, Receptors, Cytoplasmic and Nuclear, Apoptosis Regulatory Proteins, TNF-Related Apoptosis-Inducing Ligand, Osteoprotegerin, RANK Ligand, Receptor Activator of Nuclear Factor-kappa B
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.